Masimo Co. (NASDAQ:MASI) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Masimo Co. (NASDAQ:MASI) have been assigned an average rating of “Moderate Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $191.40.

Several research firms have recently weighed in on MASI. Raymond James lifted their price objective on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. Piper Sandler lifted their price objective on Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. Wells Fargo & Company lifted their price objective on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $190.00 price objective (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, January 22nd.

Institutional Trading of Masimo

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Blue Trust Inc. increased its position in shares of Masimo by 127.0% during the fourth quarter. Blue Trust Inc. now owns 286 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 160 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Masimo by 1,936.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 48,764 shares of the medical equipment provider’s stock worth $8,220,000 after acquiring an additional 46,370 shares during the last quarter. Louisiana State Employees Retirement System increased its position in shares of Masimo by 0.8% during the fourth quarter. Louisiana State Employees Retirement System now owns 12,300 shares of the medical equipment provider’s stock worth $2,033,000 after acquiring an additional 100 shares during the last quarter. Empowered Funds LLC increased its position in shares of Masimo by 85.7% during the fourth quarter. Empowered Funds LLC now owns 3,891 shares of the medical equipment provider’s stock worth $643,000 after acquiring an additional 1,796 shares during the last quarter. Finally, Lecap Asset Management Ltd. purchased a new stake in shares of Masimo during the fourth quarter worth about $1,607,000. 85.96% of the stock is owned by hedge funds and other institutional investors.

Masimo Stock Up 2.3 %

MASI opened at $181.70 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The stock has a market capitalization of $9.73 billion, a price-to-earnings ratio of 125.31 and a beta of 1.01. The business has a 50-day moving average of $171.00 and a two-hundred day moving average of $143.75. Masimo has a 12 month low of $101.61 and a 12 month high of $183.14.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating the consensus estimate of $0.84 by $0.14. The company had revenue of $504.60 million during the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.63 EPS. On average, research analysts expect that Masimo will post 4.1 earnings per share for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.